Pathology & Oncology Research

, Volume 14, Issue 1, pp 79–83

The Diagnostic Value of Macrophage Migration Inhibitory Factor (MIF) in Gastric Cancer

  • Hakan Camlica
  • Derya Duranyildiz
  • Hilal Oguz
  • Ethem Nezih Oral
  • Vildan Yasasever
Original Paper


The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum MIF, CEA, CA 19-9 levels and their various combinations in patients with gastric cancer. Study group consists of pathologically verified, gastric cancer (n = 63) and apparently healthy controls (n = 50). Serum MIF concentrations were determined by enzyme-linked immunosorbent assay (ELISA). Serum values of patients were significantly higher than the controls (p = 0.011). Diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their various combinations. The best results were achieved with the marker combination of MIF–CEA–CA 19-9 and MIF–CEA combination. In our opinion, the combination of the markers MIF–CEA is a valuable diagnostic tool for gastric cancer.


MIF CEA CA 19-9 Tumor markers Gastric cancer Accuracy 


  1. 1.
    Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res 52:6735–6470PubMedGoogle Scholar
  2. 2.
    Tahara E, Semba S, Tahara H (1996) Molecular biological observations in gastric cancer. Semin Oncol 23:307–315PubMedGoogle Scholar
  3. 3.
    Waldman TA, Heberman RH (1982) Tumor markers in diagnosis and in monitoring therapy. In: Holland JF, Frei E (eds) Cancer Medicine. Lea & Febiger, Philadelphia, pp 1068–1089Google Scholar
  4. 4.
    Klavins JV (1985) Tumor markers: clinical and laboratory studies. Alan R. Liss, New YorkGoogle Scholar
  5. 5.
    Babaian RJ, Orlando RP (1986) Elevated prostatic acid phosphatase: a prognostic factor for stage C adeno carcinoma of prostate. J Urol 136:1035–1037PubMedGoogle Scholar
  6. 6.
    Wanebo HJ, Rao B, Pinsky CM et al (1978) Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Eng J Med 299:448–451CrossRefGoogle Scholar
  7. 7.
    Molina R, Filella X, Mengual P et al (1990) MCA in patients with breast cancer: correlation with CEA and CA 15.3. Int J Biol Markers 5:14–21PubMedGoogle Scholar
  8. 8.
    David JR (1996) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl AcadSci USA 56:72–77CrossRefGoogle Scholar
  9. 9.
    Bloom BR, Bennett B (1996) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82CrossRefGoogle Scholar
  10. 10.
    Nishihira J (2000) Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. Interferon Cytokine Res 20:751–762CrossRefGoogle Scholar
  11. 11.
    Meyer-Siegler K, Hudon PB (1996) Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48:448–452PubMedCrossRefGoogle Scholar
  12. 12.
    Del Vecchio MT, Tripodi SA, Arcuri F et al (2000) Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment related changes. Prostate 45:51–57PubMedCrossRefGoogle Scholar
  13. 13.
    Kamimura A, Kamachi M, Nishihira J et al (2000) Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89:334–341PubMedCrossRefGoogle Scholar
  14. 14.
    Tomiyasu M, Yoshino I, Suemitsu R et al (2002) Quantification of macrophage inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res 8:3755–3760PubMedGoogle Scholar
  15. 15.
    Shimizu T, Abe R, Nakamura H et al (1999) High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264:751–758PubMedCrossRefGoogle Scholar
  16. 16.
    Pyle ME, Korbonits M, Gueorguiev M et al (2003) Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. Endocrinol 176:103–110CrossRefGoogle Scholar
  17. 17.
    Munaut C, Boniver J, Foidart JM et al (2002) Macrophage migration inhibitory factor (MIF) expression inhuman glioblastomas correlates with vascular endothelial growth (VEGF) expression. Neurophathol Appl Neurobiol 28:452–460CrossRefGoogle Scholar
  18. 18.
    Bando H, Matsumoto G, Bando M et al (2002) Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 93:389–396PubMedGoogle Scholar
  19. 19.
    Akbar SM, Abe M, Murakami H et al (2001) Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis: relevance to pathogenesis. Cancer Lett 171:125–132PubMedCrossRefGoogle Scholar
  20. 20.
    Legendre H, Decaestecker C, Nagy N et al (2003) Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 16:491–504PubMedCrossRefGoogle Scholar
  21. 21.
    Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122:467–481PubMedCrossRefGoogle Scholar
  22. 22.
    Yasasever V, Camlica H, Oral EN et al (1999) Utility of CEA in the Diagnosis of Patients with Cancer. J Tumor Marker Oncol 14(1):33–38Google Scholar
  23. 23.
    Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345–351PubMedCrossRefGoogle Scholar
  24. 24.
    Koprowski H, Steplewski Z, Mitchell K et al (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–972PubMedCrossRefGoogle Scholar
  25. 25.
    Bossuyt PM, Reitsma JB, Bruns DE et al (2004) Towards complete and accurate Reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 21:4–10PubMedCrossRefGoogle Scholar
  26. 26.
    Campbell MJ (1999) Medical statistics: a commonsense approach. John Wiley & Sons Inc, ChichesterGoogle Scholar
  27. 27.
    Solberg HE (1986) Textbook of clinical chemistry. W.B. Saunders Company, Lexington, pp 356–409Google Scholar
  28. 28.
    Shkolnik T, Livni E, Reshef R et al (1987) Comparison of two lymphokines (macrophage migration inhibition, leukocyte adherence inhibition factors) and carcinoembryonic antigen, in colorectal cancer and colonic premalignant lesions. Am J Gastroenterol 82:1275–1278PubMedGoogle Scholar
  29. 29.
    Shkolnik T, Livni E, Reshef R et al (1987) The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer. Studies in patients with colorectal cancer, noncolonic neoplasms, and conditions predisposing to colorectal cancer. Dis Colon Rectum 30:101–105PubMedCrossRefGoogle Scholar
  30. 30.
    He XX, Yang J, Ding YW et al (2006) Increased epithelial and serum expression of migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55:797–802PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2008

Authors and Affiliations

  • Hakan Camlica
    • 1
  • Derya Duranyildiz
    • 2
  • Hilal Oguz
    • 2
  • Ethem Nezih Oral
    • 3
  • Vildan Yasasever
    • 2
  1. 1.Preventive Oncology, Biostatistics and Epidemiology, Institute of OncologyUniversity of IstanbulIstanbulTurkey
  2. 2.Basic Oncology, Institute of OncologyUniversity of IstanbulIstanbulTurkey
  3. 3.Radiation Oncology, Institute of OncologyUniversity of IstanbulIstanbulTurkey

Personalised recommendations